NEW TARGETS
Until very recently, the understanding and availability of drug targets in Alzheimer’s has been sparse and concentrated on acetylcholinesterase, NMDA receptors or insoluble amyloid plaque. Cognition Therapeutics has taken a new approach, using the new concept that soluble Abeta oligomers are the primary neurotoxic element causing neuronal degeneration and cognitive decline in Alzheimer’s disease and discovered a brand new drug target, the sigma-2/PGRMC1 receptor.
Learn More
NEW DRUGS
The therapeutic standards of care for Alzheimer’s only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Abeta oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.
Learn More
NEW HOPE
Very recent clinical advances using Abeta monoclonal antibodies that interact with both soluble Abeta oligomers and insoluble fibrillar ABeta, have demonstrated a reduction in Abeta burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Abeta approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.
Learn MoreLatest News
Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
PITTSBURGH, October 2, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders,
Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer’s Association International Conference (AAIC) Symposium Session
Pittsburgh, July 23, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today announced that co-founder
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease
First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer’s Disease Research Unit and Yale PET Center PITTSBURGH, June 18, 2018 — Cognition Therapeutics, Inc., a clinical stage
Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action
PITTSBURGH, May 22, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other